Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of “Moderate Buy” by Brokerages

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has received an average rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $92.29.

A number of research firms have recently weighed in on RARE. JPMorgan Chase & Co. cut their price target on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, November 21st. Canaccord Genuity Group reissued a “buy” rating and issued a $121.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. Piper Sandler increased their target price on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Monday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Finally, TD Cowen boosted their target price on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, October 21st.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 11,727 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $42.23, for a total transaction of $495,231.21. Following the sale, the chief executive officer now directly owns 2,183,985 shares of the company’s stock, valued at approximately $92,229,686.55. The trade was a 0.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. True Wealth Design LLC bought a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at $43,000. Values First Advisors Inc. bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at about $56,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at approximately $83,000. Nomura Asset Management Co. Ltd. acquired a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at $93,000. Finally, Capital Performance Advisors LLP acquired a new position in Ultragenyx Pharmaceutical in the third quarter valued at about $107,000. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Trading Up 2.6 %

Shares of RARE stock opened at $43.16 on Thursday. Ultragenyx Pharmaceutical has a 52 week low of $37.02 and a 52 week high of $60.37. The company has a market cap of $3.99 billion, a PE ratio of -6.67 and a beta of 0.58. The company’s fifty day simple moving average is $46.09 and its 200-day simple moving average is $49.63.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The company had revenue of $139.49 million during the quarter, compared to analysts’ expectations of $135.28 million. During the same period in the prior year, the company posted ($2.23) EPS. The firm’s revenue for the quarter was up 42.3% on a year-over-year basis. Equities research analysts expect that Ultragenyx Pharmaceutical will post -6.2 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.